Semax has one of the strangest evidence profiles in the peptide world: a compound with decades of clinical use in one country, a registered nasal formulation, a place on a national essential-medicines list — and almost nothing in the way of the healthy-adult cognition data that drives its reputation online. If you're searching "what is semax", "semax research" or "is semax legal in australia", the most useful thing to understand up front is that the population Semax was studied in is not the population buying it. This post looks at that gap specifically: what the human data actually covers, why the dose numbers don't translate, and where Australian regulation sits.

What is Semax, and what was it built to do?

Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — derived from the ACTH(4-7) fragment of adrenocorticotropic hormone, with a Pro-Gly-Pro tail bolted onto the C-terminus. That tail isn't decorative. Native ACTH fragments are shredded by peptidases within about a minute; the Pro-Gly-Pro extension slows that cleavage considerably and gives the molecule a usable window. Critically, Semax retains the neurotrophic-type activity attributed to ACTH fragments without the hormonal (corticosteroid-releasing) activity — which is the entire design rationale.

It was developed in Russia and is registered there as nasal drops, and it appears on Russia's Vital & Essential Drugs list. Its registered clinical territory is disease: acute ischaemic stroke and transient ischaemic attack, cognitive disorders, and optic-nerve disease including ischaemic optic neuropathy. Russian ophthalmology literature from the early 2000s reports that adding Semax to standard therapy in optic-nerve disease improved the rate and extent of visual-function recovery — small, open-label, Russian-language work, not replicated in Western trials.

Note what isn't on that list: "focus", "productivity", "brain fog". Those are marketing categories, not indications.

The healthy-brain evidence is thinner than the reputation

The most-cited human study in healthy people is Kaplan and colleagues' work describing "nootropic-like activity" of Semax in humans, in which intranasal administration at around 16 µg/kg was associated with improved attention and short-term memory on testing, alongside EEG changes in cortical spectral power. It's a real study and it's the load-bearing beam under most Semax cognitive claims.

It's also small, decades old, and has not been independently replicated outside the original research lineage. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review of Semax reaches a blunt conclusion: there is a lack of compelling evidence that Semax improves cognition in healthy individuals, and no evidence for Alzheimer's disease. It notes that rigorous clinical studies are limited even for stroke — the indication with the most data — and that variability in study design and formulation means published results can't be directly applied to products sold online.

That last point deserves emphasis. Two things have to be true for a study to tell you anything useful about a product: the population has to match, and the material has to match. For Semax bought online, neither reliably does.

The dose numbers don't line up either

Healthy-volunteer work sits around 16 µg/kg — roughly a milligram or so for an adult. Russian acute-stroke protocols have used the 1% nasal formulation at 12–18 mg per day for 5–10 days, and a later open-label post-stroke study used 6,000 µg/day in two 10-day courses. Those are different strengths, different schedules and different clinical contexts separated by an order of magnitude. Anyone extrapolating a stroke-recovery result to an everyday cognitive regimen is crossing a gap the data doesn't cover.

Why "how long does semax last" is a harder question than it looks

Semax's plasma half-life is measured in minutes, not hours, because peptidases get to it quickly. Yet the biological effects attributed to it — BDNF and NGF gene expression changes, altered cortical activity — are reported to outlast the parent molecule substantially. Two explanations are offered in the literature: the peptide triggers a transcriptional cascade that continues after the peptide itself is gone, and its degradation product Pro-Gly-Pro (PGP) is itself biologically active with a longer tissue residence.

Both are plausible and both are mechanistic. Neither is a clinical duration-of-effect measurement in humans, which is what "lasts 6–8 hours" claims imply. Genome-wide transcriptional work in rat focal ischaemia has shown Semax shifting expression of immune- and vascular-system genes in ischaemic brain tissue — genuinely interesting biology, and genuinely a rat.

Is Semax legal in Australia?

Here is where Australian readers need precision rather than vibes.

Semax is unscheduled in the Poisons Standard — it isn't listed in any schedule. That is routinely misread online as "legal". It isn't the relevant test. Semax is an unapproved therapeutic good in Australia: it is not entered on the Australian Register of Therapeutic Goods, so importing, advertising or supplying it as a therapeutic product is unlawful outside a TGA pathway such as the Special Access Scheme, Authorised Prescriber or a properly approved clinical trial. "Research use only" labelling on a vial does not create a legal route for personal use.

There are no internationally registered clinical trials of Semax, which is itself telling for a compound with this much clinical history in one jurisdiction. On anti-doping, Semax does not appear on the WADA 2026 Prohibited List, though specialists describe its status as unclear — the S0 "non-approved substances" catch-all is the obvious risk for any tested athlete, and "not named on the list" is not the same as "permitted".

One practical research tip: if you go looking for Semax trials on ClinicalTrials.gov, check the sponsor before you believe the record. The registry hosts demonstration entries for peptides listing sponsors that aren't real organisations. A "RECRUITING" status line means nothing if nobody real is running it.

How to read Semax claims without getting sold

A reasonable evidence-first summary looks like this: Semax has a longer real-world clinical track record than most peptides discussed in this space, that record is concentrated in Russian-language, largely open-label studies in stroke and optic-nerve disease, the healthy-cognition data is one small strand that hasn't been replicated, and the mechanism work is mostly rodent. None of that makes it uninteresting. It makes it unproven by the standards Australian regulators actually apply.

You can read our full profile at /peptides/semax, compare it against other compounds at /peptides, and get new research summaries as they land by joining the free list at /#signup.

FAQ

What is Semax used for?

In Russia, where it is registered as nasal drops, Semax is used clinically for acute ischaemic stroke and transient ischaemic attack, cognitive disorders, and optic-nerve disease. Cognitive enhancement in healthy adults is not a registered indication anywhere.

Is Semax legal in Australia?

Semax is unscheduled in the Poisons Standard but is an unapproved therapeutic good — it isn't on the ARTG, so importing or supplying it is unlawful outside TGA pathways such as the Special Access Scheme or Authorised Prescriber.

Does Semax actually work for focus and memory?

The healthy-volunteer evidence is limited to a small number of older studies reporting attention and short-term memory changes, and it hasn't been independently replicated. The Alzheimer's Drug Discovery Foundation's review found no compelling evidence for cognitive benefit in healthy people.

Is Semax banned in sport?

Semax is not named on the WADA 2026 Prohibited List, but specialists describe its status as unclear. As a non-approved substance in most jurisdictions it could fall under the S0 category, so tested athletes should seek guidance from their anti-doping authority.

Sources

This article is information only, not medical advice, and retatrutide.net.au is independent and not affiliated with any manufacturer. Semax is not approved by the TGA and is an unapproved therapeutic good in Australia.